152 related articles for article (PubMed ID: 1953526)
1. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
Bulling MT; Wing LM; Burns RJ
Aust N Z J Med; 1991 Aug; 21(4):397-400. PubMed ID: 1953526
[TBL] [Abstract][Full Text] [Related]
2. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
[TBL] [Abstract][Full Text] [Related]
3. Trial of Sinemet CR4 in patients with Parkinson's disease.
Anderson TJ; Ewer TC; Gilchrist NL; Donaldson IM
N Z Med J; 1992 Mar; 105(929):81-2. PubMed ID: 1545941
[TBL] [Abstract][Full Text] [Related]
4. Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.
Ming A; Temlett JA; Fritz VU
J Intern Med; 1991 Aug; 230(2):113-7. PubMed ID: 1865161
[TBL] [Abstract][Full Text] [Related]
5. Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Oct; 37(10):1607-12. PubMed ID: 3658164
[TBL] [Abstract][Full Text] [Related]
6. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
Lieberman A; Gopinathan G; Miller E; Neophytides A; Baumann G; Chin L
Eur Neurol; 1990; 30(2):75-8. PubMed ID: 2340838
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.
Factor SA; Sanchez-Ramos JR; Weiner WJ; Ingenito AM
J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):83-8. PubMed ID: 2709040
[TBL] [Abstract][Full Text] [Related]
9. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
[TBL] [Abstract][Full Text] [Related]
10. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
Cedarbaum JM; Hoey M; McDowell FH
J Neurol Neurosurg Psychiatry; 1989 Feb; 52(2):207-12. PubMed ID: 2649640
[TBL] [Abstract][Full Text] [Related]
11. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Jankovic J; Schwartz K; Vander Linden C
Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
[TBL] [Abstract][Full Text] [Related]
13. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
Sage JI; Mark MH
Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
[No Abstract] [Full Text] [Related]
14. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa.
Hutton JT; Morris JL; Román GC; Imke SC; Elias JW
Arch Neurol; 1988 Aug; 45(8):861-4. PubMed ID: 3395259
[TBL] [Abstract][Full Text] [Related]
15. An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.
Olanow CW; Nakano K; Nausieda P; Tetrud JA; Manyam B; Last B; Block G; Liss C; Bush D
Clin Neuropharmacol; 1991 Jun; 14(3):235-40. PubMed ID: 2070363
[TBL] [Abstract][Full Text] [Related]
16. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
[TBL] [Abstract][Full Text] [Related]
17. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
Aarli JA; Gilhus NE
Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
[TBL] [Abstract][Full Text] [Related]
18. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.
Wolters EC; Tesselaar HJ
J Neurol; 1996 Mar; 243(3):235-40. PubMed ID: 8936353
[TBL] [Abstract][Full Text] [Related]
19. Long-term evaluation of Sinemet CR in parkinsonian patients with motor fluctuations.
Hutton JT; Morris JL
Can J Neurol Sci; 1991 Nov; 18(4):467-71. PubMed ID: 1782612
[TBL] [Abstract][Full Text] [Related]
20. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.
Ahlskog JE; Muenter MD; McManis PG; Bell GN; Bailey PA
Mayo Clin Proc; 1988 Sep; 63(9):876-86. PubMed ID: 3045435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
